Sphera Funds Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Sphera Funds Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,000	Closed	-$332K	–	107
2019 Q2	$332K	Buy	+20,000	New	+$347K	0.05%	86
2017 Q3	–	Sell	-332,855	Closed	-$1.82M	–	150
2017 Q2	$1.82M	Hold	332,855	–	–	0.31%	86
2017 Q1	$2.36M	Sell	332,855 -2,292	-0.7%	-$12.3K	0.46%	64
2016 Q4	$1.35M	Hold	335,147	–	–	0.34%	74
2016 Q3	$2.44M	Buy	335,147 +42,486	+15%	+$287K	0.4%	65
2016 Q2	$1.49M	Buy	292,661 +149,934	+105%	+$2.76M	0.39%	67
2016 Q1	$3.07M	Hold	142,727	–	–	0.67%	26
2015 Q4	$4.36M	Buy	142,727 +102,197	+252%	+$3M	0.64%	28
2015 Q3	$1.35M	Sell	40,530 -34,103	-46%	-$1.92M	0.17%	110
2015 Q2	$3.46M	Buy	74,633 +21,250	+40%	+$794K	0.34%	72
2015 Q1	$1.92M	Sell	53,383 -20,000	-27%	-$878K	0.2%	108
2014 Q4	$3.09M	Hold	73,383	–	–	0.53%	60
2014 Q3	$1.9M	Buy	+73,383	New	+$2.27M	0.23%	94

Other funds holding MRNS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Sphera Funds Management's MRNS Position: Q3 2019 in Review

Sphera Funds Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2019, closing a stake of 20,000 shares — an estimated $332K sold.

Sphera Funds Management first reported a position in MRNS in Q3 2014 and held it in 13 quarters. The position peaked at $4.36M in Q4 2015. 64 funds tracked by Wall St. Rank hold MRNS as of Q3 2019.

Sphera Funds Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
Sphera Funds Management sold 20,000 Marinus Pharmaceuticals, Inc shares in Q3 2019, an estimated $332K.
Sphera Funds Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2014 and held it in 13 quarters.
Sphera Funds Management's Marinus Pharmaceuticals, Inc position peaked at $4.36M in Q4 2015.
64 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2019.

Based on Sphera Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.